Some of my biggest investment disappointments have come from getting carried away by the size of a market, prior to the company in question having a product or service to compete in that market.
Worse, when people start saying "even if we only get xxx% of that market,,,,,,"
I understand that big pharma often gamble exactly on a drug's potential, and would have to base a valuation on something, but that wasn't the point of this post.
At this point, I'm sitting back and enjoying watching a well run and honest company try and achieve something remarkable for people suffering with Cancer. To that end, something quite amazing has happened over the past few months. I unashamedly bought in to this hoping to make a few quid. That's why we invest - right?
But having lost both parents, and seen countless other people in my life, or in the lives of those that matter to me, lost to, or affected by, various forms of cancer, I've gone from worrying about the financial return this may or may not ultimately produce, to becoming fixated on it's success in the medical sense, and enjoying learning a little bit about the science behind cancer treatments, and the progress of Bisantrene on several fronts.
I can't imagine how you must feel Dr T, working on this project each day. The very obvious, and significant financial benefit you would receive from shares owned and performance options held notwithstanding, the money must surely pale in to insignificance when you think about the amount of lives that could be changed, and saved, purely because of the work the RAC team is putting into developing a better way to treat cancers.
No matter the size of this market, I hope Bisantrene swallows up the lot, if it offers a better chance of survival to those fighting for their lives.
The money would be great, and it's fun to speculate and discuss. But I bet most of us would give it up in a heartbeat to get back somebody we'd lost, or that we knew was fighting cancer right now.....
Expand
(20min delay)